News

Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) issued the following statement after the United States Supreme Court struck down the “Chevron Deference” in Loper Bright Enterprises, et al. v. Raimondo : “Article I of the Constitution established Congress’s role to write the laws of the land—not the Executive Branch. The Supreme Court’s ruling today will help restore the proper balance of power as the Founders envisioned it. Moving forward, major decision-making authority will no longer automatically be deferred to unelected, unaccountable bureaucrats. Power has been placed back in the hands of the American people and their elected representatives, as the Constitution prescribes.” 

Washington D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) delivered the following opening remarks at today’s Oversight and Investigations Subcommittee hearing titled “Examining Anti-Doping Measures in Advance of the 2024 Olympics.”  “Thank you, Chair Griffith, and thank you to our highly decorated panel of witnesses whose Olympic careers have inspired an entire generation of Americans.  “Tonight’s hearing comes at an important moment as we are just one month away from the start of the 2024 Summer Olympic games in Paris.  “We will be examining how the World Anti-Doping Agency’s polices—and their failure to enforce those policies—on the use of banned performance enhancing drugs and how that is undermining the integrity of the Olympic games.”  WADA REFUSES ACCOUNTABILITY   “It is completely unacceptable that World Anti-Doping Agency President Witold Banka, whose agency received over three million in U.S. taxpayer dollars this past year, declined to join us tonight.  “Doping scandals have real effects on our athletes, including American swimmers, who must abide by the strictest anti-doping standards enforced by USADA, and include requirements like random testing.  “These anti-doping standards should be applied evenly to ensure a level playing field and that the best athlete wins.”  CHINESE DOPING SCANDAL “Recent reporting unveiled that just weeks before the 2021 Olympic games in Tokyo, 23 members of the Chinese swimming team tested positive for a banned substance—Trimetazidine or TMZ.   “The Chinese authorities dismissed the positive tests, telling the World Anti-Doping Agency this was all a mistake because the banned drug—which is found only in pill form—somehow ended up in the kitchen of a hotel that all 23 swimmers were staying at, and they all somehow unknowingly ingested this banned substance.  “The World Anti-Doping Agency’s review somehow concluded this explanation was plausible and no further investigation was necessary.  “It’s important to note that those swimmers won several medals, including three golds.  “WADA has consistently failed to be transparent or accept any responsibility for its actions.  “And it’s not just the US Congress.  “WADA also declined a hearing invitation from the German Bundestag that was scheduled earlier this month.    “How many more Olympic athletes have to lose out on winning medals and proudly singing their country’s national anthem before the World Anti-Doping Agency decides to enforce its rules uniformly?  “Everyone watching the Olympics in Paris and in their homes next month should know that the system is not rigged against athletes who compete the right way.  “I look forward to hearing from all of you on this important topic.” 

Washington D.C. —  House Energy and Commerce Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA) delivered the following opening remarks at today’s subcommittee  hearing  titled “Examining Anti-Doping Measures in Advance of the 2024 Olympics.”  UPHOLDING THE INTEGRITY OF THE OLYMPICS   “As U.S. athletes prepare to compete in the Paris Olympics, a cloud of uncertainty hangs over the reliability of international anti-doping enforcement which is supposed to eliminate the use of certain performance enhancing drugs.  “This Committee has been alarmed to learn from news reports that several swimmers representing the People’s Republic of China tested positive for banned performance enhancing substances and then went on to compete in the 2021 Tokyo Olympics.  “Just last week, eleven of these swimmers were again named to the People’s Republic of China’s 2024 Olympic team. All of this comes after the World Anti-Doping Agency, or WADA, ignored signs of systemic Russian doping for years.  “Seven years ago, this Oversight subcommittee, held a hearing on ways to strengthen the international anti-doping system. It is unfortunate that we are here again.  “Two witnesses from that 2017 hearing are back with us today—premier Olympian, Mr. Michael Phelps and the CEO of the United States Anti-Doping Agency, or USADA, Mr. Travis Tygart.  “We are also pleased to welcome another outstanding Olympic swimmer, Ms. Allison Schmitt, to join us today so we can revisit doping in sports ahead of next month’s Summer Olympics. “I want to start off by reminding everyone of what Mr. Phelps told us seven years ago, because it bears repeating. “He said ‘if we allow our confidence in fair play to erode, we will undermine the power of sport and the goals and dreams of future generations. The time to act is now.’  “I’m glad Mr. Phelps highlighted the damage performance enhancing drugs has on our country’s youth athletes and am disappointed that WADA has not seemed to heed that call.” THE IMPORTANCE OF A LEVEL PLAYING FIELD   “Children join sports teams and clubs believing that the system is mostly fair and that cheaters will be punished.  “The importance of sports for our country’s children cannot be understated.  “Sports empower children by teaching them life lessons, building their confidence, showing them the meaning of hard work, and offering some of them opportunities to represent our country and make a career. “I myself have had the opportunity to see my own children grow and learn from competitive swimming.   “In fact, this last week was very exciting in my household, because one year ago, in high school regionals, my son competed against Olympian Thomas Heilman, who at age 17, is the youngest male swimmer to qualify for Team USA since Michael Phelps.  “The joke at my house was, that, at one point in the race they were tied, that would be the part where the starter says, 'take your mark.’  “Foundational to the Olympics is the trust that clean athletes, both aspiring and current Olympians, have in the system to keep cheaters out.   “Doping leads to cynicism in sports and inevitable disappointment for aspiring athletes. “As I’m sure Ms. Schmitt and Mr. Phelps can attest to, we cannot overemphasize the dedication, sacrifices, and training required of our Olympians, competing at the very highest, and what I believe to be the most prestigious, athletic level. “Youth athletes dedicate themselves by putting in countless hours of training, pushing both physical and mental limits in the hopes of one day being an Olympian.   “Athletes miss birthdays and holidays to train so that they can achieve success the right way, on their merit.  “Mr. Phelps has previously said he didn’t take a single day off for over a five-year period, just so he could be the best at what he does.  “Doping irrevocably undermines the purpose of that sacrifice by allowing competitors who really want all the glory without putting in as much work.  “Is it fair that we encourage our youth to invest so much of their time if on the greatest stage consequences are not expected for certain countries’ athletes?”  WADA MUST IMPROVE TRANSPARENCY   “That is why I am disappointed that Mr. Banka, the President of WADA, refused our invitation to testify before this Subcommittee today to discuss his role in upholding the integrity of anti-doping testing and enforcement in international sports competitions.  “WADA received nearly four million in taxpayer dollars through Congress last fiscal year. Their refusal to appear today calls into question their commitment to accountability and perhaps if they’re not going to do their job, should we even fund them?  “Mr. Banka and WADA have hidden today rather than explain how WADA let over twenty swimmers representing the People’s Republic of China compete in international competitions after they all tested positive for a banned substance.  “Cheating athletes take away spots and medals from clean athletes.  “The integrity and sanctity of sports is critical for the Olympians competing but also for the children who dream one day to be an Olympian.  “We will keep a seat open for Mr. Banka in case he decides to join us.  “I want to thank the three of you who made it here today despite your very busy schedules ahead of the Paris Olympics.” 

Washington, D.C. — In a new letter to Food and Drug Administration (FDA) Commissioner Robert Califf, House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) are pressing for more information regarding the agency’s foreign drug inspection program. The letter continues the Committee’s investigation into FDA inspection practices, which include a July 18, 2023, letter , a December 13, 2023, letter , and a February 6, 2024, oversight hearing at which the FDA declined to make an official available to testify.  BACKGROUND :  In the letter, the Members discuss the Committee’s analysis of FDA inspection outcomes in India and China from January 2014 to April 2024, limiting its review to inspectors with ten or more inspections in either China or India.   EXCERPT OF THE ANALYSIS :  “The results of this analysis were surprising, revealing tremendous variation in inspection outcomes. Some FDA inspectors found compliance issues during all or almost all of their inspections. Other inspectors rarely reported finding a single compliance issue. Two inspectors never found a single compliance issue over the course of a combined 24 inspections in India. Another inspector found zero compliance issues in 20 out of 23 inspections (85 percent) in China while finding compliance issues with almost half of domestic inspections during the same period. These are unusual inspection outcomes, the opposite of what would be expected given the widely reported failures in quality control and lack of adherence to current good manufacturing techniques by drug manufacturing facilities in China and India.  “By contrast, 16 FDA inspectors, with over 325 inspections collectively in India, found compliance issues during every inspection they conducted. As a measure of what a pattern of rigorous inspections should look like, the Committee reviewed the inspection outcomes for 3 FDA inspectors with professional reputations for thoroughness who also had at least 10 inspections in China or India during the studied time period. These expert inspectors reported finding no compliance issues during inspections in China at a rate of only 6.7 to 11.4 percent and at a rate of zero to 9.5 percent in India.”  KEY LETTER EXCERPT : “Such large variations in inspection outcomes are troubling, and they merit further investigation. At a minimum, the Committee is concerned that these findings suggest vast differences in the skill, thoroughness, and competence of FDA inspectors. The difference in inspection outcomes appears to be just another example of institutional weaknesses and dysfunction in the FDA’s foreign drug inspection program. Prior to the pandemic, media reporting found that some FDA inspectors took an inappropriately lenient approach with foreign drug manufacturers with serious compliance violations. There were also reports o f, and concerns about, foreign manufacturers attempting to bribe or improperly influence inspectors. The Committee is seriously evaluating the disturbing possibility that some of the variation in inspection outcomes could be the result of bribery or fraud.”  CLICK HERE to read the full letter. 

Today, the House Energy and Commerce Committee is holding an Oversight Subcommittee hearing anti-doping measures ahead of the 2024 Olympic games. Chair Cathy McMorris Rodgers (R-WA) joined Spectrum News to highlight the importance of this hearing. Highlights and excerpts from the interview below:   “[This] is an oversight hearing to ask tough questions to ensure transparency and accountability and give people here at home, and around the world, the confidence that the rules are being followed.”   [...]  “The United States contributes millions of dollars to the World Anti-Doping Agency, and it's important that we are getting answers.”  [...]  “Our athletes train for years. They dedicate their lives to training and participating and being able to compete at the Olympics and our responsibility is to ensure that this is a level playing field.”  “That's why we're holding this hearing, so that we can root on the best of the best from the United States as they compete in Paris at the Olympics.”  Background:   The Committee’s hearing comes after the World Anti-Doping Agency (WADA) allowed 11 Chinese swimmers to compete in the 2024 Paris Olympics, despite testing positive for banned performance-enhancing substances in the lead up to the 2021 Tokyo Olympics.  The United States is the primary funder of WADA, contributing over $3 million of taxpayer money this past year alone.  WADA President Witold Banka was invited to testify but declined.  Hearing Details: DATE: Tuesday, June 25, 2024   TIME: 7:00 PM ET   LOCATION: 2123 Rayburn House Office Building   CONFIRMED WITNESSES: Mr. Michael Phelps, Olympic Athlete Ms. Allison Schmitt, Olympic Athlete   Mr. Travis Tygart, Chief Executive Officer, U.S. Anti-Doping Agency Click here for more coverage on the hearing. 

Former Olympians Michael Phelps & Allison Schmitt scheduled to testify Washington, D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) announced a hearing titled “Examining Anti-Doping Measures in Advance of the 2024 Olympics.” “Olympic athletes dedicate years of their lives to perfect their craft in order to represent the United States on the world stage. They—as well as athletes from every other country—deserve to compete on a level playing field that’s free of banned performance enhancing drugs,” said Chairs Rodgers and Griffith. “The World Anti-Doping Agency, the governing body responsible for enforcing fair standards, has a questionable track record of fulfilling that mission. This hearing will give Members a chance to examine that track record, identify opportunities for improvement, and ensure that the best athletes are the ones taking home gold medals.”  Subcommittee on Oversight and Investigations hearing titled “Examining Anti-Doping Measures in Advance of the 2024 Olympics.”   WHAT: A Subcommittee on Oversight and Investigations hearing to examine anti-doping measures ahead of the 2024 Olympics.  DATE: Tuesday, June 25, 2024  TIME: 7:00 PM ET  LOCATION: 2123 Rayburn House Office Building  CONFIRMED WITNESSES:    Mr. Michael Phelps, Former Olympic Athlete  Ms. Allison Schmitt, Former Olympic Athlete  Mr. Travis Tygart, Chief Executive Officer, U.S. Anti-Doping Agency  INVITED WITNESSES :  Mr. Witold Banka, President, World Anti-Doping Agency This notice is at the direction of the Chair. The hearing will be open to the public and press and will be live streamed online at https://energycommerce.house.gov/ . If you have any questions concerning the hearing, please contact Lauren Kennedy with the Committee staff at Lauren.Kennedy@mail.house.gov . If you have any press-related questions, please contact Christopher Krepich at Christopher.Krepich@mail.house.gov .  

Washington, D.C. — The House Energy and Commerce Committee today released a report titled “Interim Staff Report into Risky MPXV Experiment at the National Institute of Allergy and Infectious Diseases.”  The report details the Committee’s investigation, which was launched following a 2022 Science magazine interview in which Dr. Bernard Moss of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) revealed that he was planning to insert segments of a lethal strain of MPXV (formerly known as “monkeypox”) into a more a transmissible strain of the virus. This proposed experiment alarmed some scientists concerned about the risks of creating an enhanced version of the MPXV virus.  For nearly a year and a half, the Department of Health and Human Services (HHS), the NIH, and NIAID misrepresented and deceived the Committee by repeatedly denying that the potentially dangerous experiment was proposed and approved. However, after being pressed repeatedly by Committee Leaders, HHS ultimately admitted Dr. Moss’s research team had been granted approval to conduct a bidirectional MPVX gene-transfer experiment (i.e., inserting the more lethal strain into the more transmissible strain and vice versa). Documents made available for review to Committee staff confirmed the 2015 approval of the experiment and raised additional concerns.   HHS, the NIH, and NIAID still maintain the riskier research project was never conducted. However, no documentation or any other evidence has been produced to substantiate the claim. NIAID has also failed to offer any explanation of the circumstances and rationale that supposedly led the Moss research team to drop the bidirectional mpox gene-transfer experiment after receiving approval for the project.  The report concludes with a series of recommendations related to biosecurity to ensure future transparency and accountability related to risky research like this. Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) released the following statement regarding the report:  “In order to start rebuilding trust in our government health agency guidance, agencies like the NIH must be honest and transparent with Congress and the American people. This report demonstrates a disturbing lack of judgment and accountability from HHS, the NIH, and particularly, NIAID. It is unacceptable and demonstrates the clear need for reform.”  CLICK HERE to read the full report.  TIMELINE OF THE INVESTIGATION :

Washington D.C. — House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) delivered the following opening remarks at today’s Oversight and Investigations Subcommittee hearing titled “Oversight of 340B Drug Pricing Program.”   “This hearing is an opportunity for us to evaluate recent trends and developments in the health care system that impact the 340B Drug Discount Program. “The 340B Program was created by Congress to ‘enable covered entities to stretch scarce federal resources to reach more eligible patients and provide more comprehensive services.’ “It's a worthy goal and a seemingly straightforward one. “For community health centers, high disproportionate share hospitals, and rural providers, savings from the 340B Program are critical. “In some cases, savings from the 340B Program are helping keep the lights on at what may be the only hospital in a rural community, and those cases reflect the spirit and intent of the law to ensure essential services for our most vulnerable communities.”  UNCLEAR BENEFITS FOR VULNERABLE PATIENTS   “With that said, I worry that the program is being co-opted by larger, more profitable health care systems that are using it solely for financial gain at the expense of the patients that who it most. “We have talked a lot in this Committee about addressing the impacts that high health care costs have on patients, employers, and taxpayers, and how we need to work to create a simpler and more transparent health care system. “Every single one of us pays for the high cost of health care, whether that’s at the doctor’s office, through our insurance premiums, or in taxes that cover the ever-increasing costs of Medicare and Medicaid. “Something that’s become increasingly clear is that the 340B Program is distorting markets and behaviors in our health care systems that are increasing costs for all of us. “In multiple studies, researchers found that the 340B Program was associated with a nearly 25 percent reduction in the prescribing biosimilars and other lower-cost drugs in favor of more expensive brand name alternatives, so that hospitals could pursue larger savings from the program, even though patients’ out-of-pocket costs are not tied to any of the savings that the hospital may receive. “Additionally, the New England Journal of Medicine found that the program further incentivizes hospital systems to acquire independent oncology practices, so that they can expand their 340B footprint. “Some will argue that hospitals reinvest these savings in ways consistent with the intent of the program, but there’s little evidence to prove this.” INCREASING ACCESS TO CARE “This Committee has focused so much effort over the past two years on increasing transparency in health care, tackling incentives in the prescription drug market that push up health care costs for Americans, and addressing site neutrality and other reforms that are driving consolidation. “It should be a bipartisan goal for every member on this Committee to apply the same principles to the 340B Program as well. “Let me reaffirm once more that I support this program in its original intent and mission. “Last year, we heard from Pullman Regional Hospital in my district about the value that the 340B Program provides to them and other hospitals across the country. “We’ve also heard testimony in support of increased transparency for the program so that we can, at the very least, understand how covered entities are using this program. “If we are serious about lowering health care costs for Americans, then we must also take a critical look at the 340B Program and make sure it is achieving its intended mission.” 

Washington D.C. — House Energy and Commerce Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA) delivered the following opening remarks at today’s subcommittee hearing titled “Oversight of 340B Drug Pricing Program.”  “Today’s hearing is an opportunity to examine the 340B drug pricing program. “I will start by saying this is a personal hearing for me because this topic is something I made a promise to my dear friend and fellow Virginia member, Don McEachin, that I would do before he passed away. “He called me regarding a 340B report relating to his district before the election and a couple of weeks before his unexpected death and said, 'If you are chairman of Oversight and Investigations on Energy and Commerce, I need your help on 340B.’ I promised him I would help. “So, I am glad we are doing this hearing and fulfilling that promise.” 340B’S ORIGINAL MISSION “The 340B program was established by Congress to allow certain covered entities that provide care to a large number of underserved patients to purchase drugs at significant discounts from manufacturers.  “In theory, the savings these covered entities yield from receiving the discounted drug is meant to be passed along to patients and to be reinvested into that community to help provide additional care or resources.   “But, it is not mandated to disclose where these dollars go and how much they made from this program. It is mostly a black box as to what happens with these dollars.   “When the Affordable Care Act was signed into law in 2010, the program rapidly expanded by allowing more entities to receive the discounted 340B price for drugs.    “The number of covered entities participating in the 340B program has increased from 8,000 in 2000 to more than 50,000 in 2020.   “Today, the 340B program accounts for almost $54 billion in annual discounted sales. Making it the second largest federal prescription drug program.   “I am a supporter of the overall 340B program.   “There are many hospitals, including in my district, who are appropriately using the 340B dollars to keep their doors open and heavily rely on this program.  “Yet, we see reports about entities taking advantage of the system. And that is what caused my friend, Don McEachin, to reach out.”  ABUSE OF THE 340B SYSTEM   “The New York Times reported on how Bon Secours hospital system apparently used the Richmond Community Hospital, in Virginia, which serves predominately poor patients, to expand its use of 340B at the expense of Richmond Community Hospital and patients in that community.  “The New York Times asserted that over the years, services at this Richmond Community Hospital were slashed and departments closed, while Bon Secours used the hospital as a piggy bank and transferred millions out of Richmond to other hospitals within the system, possibly as far away as Ohio.   “This is the reverse Robin Hood. Steal from the poor to pay the rich.   “One specific example in this report was Bon Secours using the Richmond Community Hospital to purchase a cancer drug for more than $3,000 and then turning around and selling that same drug they bought under the 340B discount for more than $25,000 to a private insurer.   “That could be an almost $22,000 in profit alone from one single vial for one patient.  “When reports like the Bon Secours situation occur, it is Congress’s job to step in and provide oversight into this program.”  ENSURING 340B IS EXPANDING ACCESS TO CARE   “The 340B program is a lifeline for many hospitals, health clinics, community health centers, and many other health care facilities.   “My district has more than 50 community health centers and 340B serves as a critical tool to help keep their doors open and to provide additional services for my constituents.   “When I visit these centers and hospitals in my district, they are very open about where their 340B dollars go.   “That is because my district is economically stressed, and health care providers rely on these dollars to serve their patients.   “I believe creating more transparency in the program so we can see where the dollars are flowing and ensuring the program is not being taken advantage of is the first step.   “This will allow Congress to understand the full picture and ensure that the patients are the ones reaping the benefits of this program.  “The patient is the one who must come first in this, and they should not be caught in the crosshairs of any of the issues we will hear about today.”